RYCLORA™ (dexchlorpheniramine maleate) Oral Solution, USP

Manufacturer
CARWIN PHARMACEUTICAL ASSOCIATES, LLC
Effective date
2024-01-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:57:31

Label at a glance#

ProductRYCLORA
Active ingredientDexchlorpheniramine Maleate
Label structure13 sections

Indications and uses

Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Dosage and administration

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. Adults and Children 12 years of age and older: 2 mg (1 teaspoonful) Children 6 to 11 years: 1 mg (1/2 teaspoonful) Children 2 to 5 years: 0.5 mg (1/4 teaspoonful) Doses are generally given every 4 to 6 hours.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Each 5 mL (teaspoonful) contains:
Dexchlorpheniramine Maleate, USP2 mg

Dexchlorpheniramine Maleate, USP, an antihistamine agent, is a white, odorless crystalline powder that is freely soluble in water. The molecular formula is C16H19ClN2 ∙ C4H4O4, designated chemically as (+)-2-[p-Chloro-α-[2-(dimethylamino)ethyl]benzyl] pyridine maleate (1:1).

Chemical Structure
Chemical Structure

M.W. = 390.86

Inactive Ingredients: Citric acid, cherry flavoring, FD&C Red No. 40, glycerin, menthol, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate dihydrate, and sugar.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Dexchlorpheniramine maleate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Perennial and seasonal allergic rhinitis

Vasomotor rhinitis

Allergic conjunctivitis due to inhalant allergens and foods

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

Amelioration of allergic reactions to blood or plasma

Dermographism

As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Use in Newborn or Premature Infants

SPL UNCLASSIFIED SECTION

This drug should not be used in newborn or premature infants.

Use in Nursing Mothers

SPL UNCLASSIFIED SECTION

Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Use in Lower Respiratory Disease

SPL UNCLASSIFIED SECTION

Antihistamines should NOT be used to treat lower respiratory tract symptoms including asthma.

Antihistamines are also contraindicated in the following conditions:

  1. Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure
  2. Monoamine oxidase inhibitor therapy (See Drug Interaction section)

WARNINGS

WARNINGS SECTION

Antihistamines should be used with considerable caution in patients with:

  1. Narrow angle glaucoma
  2. Stenosing peptic ulcer
  3. Pyloroduodenal obstruction
  4. Symptomatic prostatic hypertrophy
  5. Bladder neck obstruction

Use in Children

SPL UNCLASSIFIED SECTION

In infants and children, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death.

As in adults, antihistamines may diminish mental alertness in children. In the young child, particularly, they may produce excitation.

Use in Pregnancy

SPL UNCLASSIFIED SECTION

Experience with this drug in pregnant women is inadequate to determine whether there exists a potential for harm to the developing fetus.

Use with CNS Depressants

SPL UNCLASSIFIED SECTION

RYCLORA™ Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).

Use in Activities Requiring Mental Alertness

SPL UNCLASSIFIED SECTION

Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Use in the Elderly (approximately 60 years or older)

SPL UNCLASSIFIED SECTION

Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS

PRECAUTIONS SECTION

RYCLORA™ Oral Solution has an atropine-like action and, therefore, should be used with caution in patients with:

History of bronchial asthma
Increased intraocular pressure Hyperthyroidism
Cardiovascular disease
Hypertension

Drug Interaction

DRUG INTERACTIONS SECTION

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

  1. General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and the throat.
  2. Cardiovascular System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
  3. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
  4. Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
  5. G.I. System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
  6. G.U. System: Urinary frequency, difficult urination, urinary retention, early menses.
  7. Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

Call your doctor for medical advice about side effects. You may voluntarily report side effects to FDA at 1-800-FDA-1088. Questions or comments? Call Carwin Pharmaceutical Associates, LLC at 1-844-700-5011.

OVERDOSAGE

OVERDOSAGE SECTION

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms—dry mouth, fixed, dilated pupils, flushing, and gastrointestinal symptoms may also occur.

If vomiting has not occurred spontaneously the patient should be induced to vomit. This is best done by having the patient drink a glass of water or milk after which the patient should be made to gag. Precautions against aspiration must be taken, especially in infants and children.

Saline cathartics, such as milk of magnesia, draw water into the bowel by osmosis and therefore, are valuable for their action in rapid dilution of bowel content.

Stimulants should not be used.

Vasopressors may be used to treat hypotension.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

HOW SUPPLIED

HOW SUPPLIED SECTION

RYCLORA™ Oral Solution is supplied as a red colored, cherry flavored liquid in the following sizes:

4 fl oz (118 mL), NDC 15370-150-04
16 fl oz (473 mL), NDC 15370-150-16
0.7 fl oz (20mL), NDC 15370-150-99 (as physician sample)

SPL UNCLASSIFIED SECTION

Rx Only

Manufactured for:
Carwin Pharmaceutical Associates, LLC
Hazlet, NJ 07730
www.carwinpharma.com

500403-01

REV. 03/2018

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 15370-150-16

RyClora™
(dexchlorpheniramine maleate)

Oral Solution, USP
2 mg/5 mL

Cherry Flavor

Rx Only
16 fl. oz (473 mL)

carwin
PHARMACEUTICAL ASSOCIATES

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2183907dexchlorpheniramine maleate 2 MG in 5 mL Oral SolutionPSN2
2183912RyClora 2 MG in 5 mL Oral SolutionPSN2
2183912dexchlorpheniramine maleate 0.4 MG/ML Oral Solution [Ryclora]SBD2
2183907dexchlorpheniramine maleate 0.4 MG/ML Oral SolutionSCD2
2183907dexchlorpheniramine 2 MG per 5 ML Oral SolutionSY2
2183912Ryclora 0.4 MG/ML Oral SolutionSY2
2183912Ryclora 2 MG per ML Oral SolutionSY2

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
44893bf2-1be4-4e68-8bc4-bbb0f543085eProduct name120180830

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
15370-150-04RYCLORA118 mL in 1 BOTTLE, PLASTICLIQUID1182
15370-150-16RYCLORA473 mL in 1 BOTTLE, PLASTICLIQUID4732
15370-150-99RYCLORA20 mL in 1 BOTTLE, PLASTICLIQUID202

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
15370-150RYCLORA (DEXCHLORPHENIRAMINE MALEATE) LIQUID [CARWIN PHARMACEUTICAL ASSOCIATES, LLC]2Current NDC, Legacy NDC, 3 package rows20240109_aa4f80c9-e600-4bc0-8528-02a8162a36f0.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
15370-150-04ML - Milliliter15370-150a77c55bc-c83a-4f41-8b4c-fd2d4df7449b12018-11-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
15370-15015370-150-16, 15370-150-04, 15370-150-99

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A202520-001POLMONDEXCHLORPHENIRAMINE MALEATE2MG/5MLSYRUP / ORALRS2018-07-16

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-1684e616aacf4f…
2026-08-18 06:07:402026-07A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-1631067a03dcf5…
2025-08-23 18:47 UTC2025-08A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-166a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-1603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-162680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-165bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-1679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-16301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-161e350fbaab3a…
2024-05-31 18:47 UTC2024-05A202520-001POLMON2MG/5MLSYRUP / ORALRS2018-07-168072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-165c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-165d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-164b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-1674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-1687673890dc5c…
2021-03-12 10:30 UTC2021-03A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-165aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-168869cabd3fbd…
2020-11-12 02:37 UTC2020-11A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16c0c555d07b60…
2019-12-14 00:12 UTC2019-12A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-163f01610625f2…
2019-09-15 20:21 UTC2019-09A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16b00525d2431f…
2019-07-19 19:46 UTC2019-07A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-166a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-161c564ffb4f44…
2023-12-20 04:57 UTC2023-12A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-169b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-163f0d92c62455…
2023-05-13 08:27 UTC2023-05A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16053a50430f4f…
2023-01-26 05:58 UTC2023-01A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-163bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-163a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A202520-001POLMON2MG/5MLSYRUP / ORALAA2018-07-16f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202520-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A202520-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A202520-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A202520-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A202520-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A202520-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A202520-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A202520-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A202520-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A202520-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A202520-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A202520-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A202520-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A202520-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A202520-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A202520-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A202520-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A202520-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A202520-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A202520-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A202520-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A202520-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A202520-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A202520-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A202520-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A202520-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RYCLORADEXCHLORPHENIRAMINE MALEATECARWIN PHARMACEUTICAL ASSOCIATES, LLCaa4f80c9-e600-4bc0-8528-02a8162a36f02024-01-08Warnings, Adverse reactionsExact identifier
ndc (package): 15370-150-16
ndc (package): 15370-150-04
ndc (package): 15370-150-99
ndc (product): 15370-150
ndc11 (package): 15370015004
ndc11 (package): 15370015016
ndc11 (package): 15370015099
spl id: 3affdd03-252d-443c-9966-e3aec314fb98
spl set id: aa4f80c9-e600-4bc0-8528-02a8162a36f0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.